Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease.

Percutaneous coronary revascularization strategies have gradually progressed over a period of last few decades. The advent of newer generation drug-eluting stents has significantly improved the outcomes of Percutaneous Coronary Intervention (PCI) by substantially reducing in-stent restenosis and stent thrombosis. However, vascular inflammation, restenosis, thrombosis, and neoatherosclerosis due to the permanent presence of a metallic foreign body within the artery limit their usage in complex Coronary Artery Disease (CAD). Bioresorbable Scaffolds (BRS) represent a novel approach in coronary stent technology. Complete resorption of the scaffold liberates the treated vessel from its cage and restores pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. In this review article, we describe the advances in this rapidly evolving technology, present the evidence from the pre-clinical and clinical evaluation of these devices, and provide an overview of the ongoing clinical trials that were designed to examine the effectiveness of BRS in the clinical setting.

• Publication year

  2016

• Venue

  Journal of clinical and diagnostic research : JCDR

• Publication date

  2016-10-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.7860/JCDR/2016/21915.8429PMID 27891384PMCID PMC5121722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serial intravascular ultrasound evaluation of the DESolve™ novolimus‐eluting bioresorbable coronary scaffold system

  2018cited by this paper
• Design and characterization of a novel biocorrodible iron-based drug-eluting coronary scaffold

  2016cited by this paper
• Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention

  2016cited by this paper
• A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.

  2015cited by this paper
• Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months.

  2014cited by this paper
• Current status of bioresorbable scaffolds in the treatment of coronary artery disease.

  2014cited by this paper
• A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.

  2014cited by this paper
• Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.

  2014cited by this paper
• Bioresorbable scaffolds: rationale, current status, challenges, and future.

  2014cited by this paper
• Coronary stents: historical development, current status and future directions.

  2013cited by this paper
• Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.

  2013cited by this paper
• TCT-39 12-Month Angiographic and Clinical Results of the ReZolve(r) Sirolimus-Eluting Bioresorbable Coronary Scaffold: The RESTORE trial

  2013cited by this paper
• Bioresorbable scaffolds in the treatment of coronary artery disease

  2013influential reference
• Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-l-Lactic Acid Coronary Stents: Igaki-Tamai Stents

  2012cited by this paper
• First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

  2012cited by this paper
• Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?

  2011cited by this paper
• 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm.

  2011cited by this paper
• Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.

  2010cited by this paper
• Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents.

  2009cited by this paper
• A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.

  2009cited by this paper
• OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings.

  2009cited by this paper
• A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial.

  2008cited by this paper
• Novel bioabsorbable salicylate‐based polymer as a drug‐eluting stent coating

  2008cited by this paper
• Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology.

  2008cited by this paper
• Coronary bioabsorbable magnesium stent: 15-month intravascular ultrasound and optical coherence tomography findings.

  2007cited by this paper
• Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials

  2007cited by this paper
• Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach

  2007cited by this paper
• Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.

  2007cited by this paper
• Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach.

  2007cited by this paper
• Control of smooth muscle cell proliferation by ferrous iron.

  2006cited by this paper
• Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries

  2006cited by this paper
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• FRS-177 Four-year Follow-up of the Biodegradable Stent (IGAKI-TAMAI Stent)(Percutaneous Coronary Intervention (IHD) : FRS21)(Featured Research Session (English))

  2004cited by this paper
• Left main coronary artery fistula exiting into the right atrium

  2003cited by this paper
• A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

  2002cited by this paper
• A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

  2002influential reference
• Thrombogenicity of the human arterial wall after interventional thermal injury.

  1996cited by this paper
• Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.

  1996cited by this paper
• A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease

  1994cited by this paper
• A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.

  1994cited by this paper
• A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.

  1994cited by this paper
• Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment.

  1993cited by this paper
• Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty

  1992cited by this paper
• Angiographic follow-up after placement of a self-expanding coronary-artery stent.

  1991cited by this paper
• Emergency stenting for acute occlusion after coronary balloon angioplasty.

  1988cited by this paper
• Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty.

  1979cited by this paper
• Transluminal dilatation of coronary-artery stenosis.

  1978cited by this paper
• Transluminal dilatation for coronary-artery stenosis.

  1978cited by this paper
• Treatment of coronary artery disease.

  1946cited by this paper
• The Netherlands Source: Cbs/cheps Higher Education Monitor

  year unknowncited by this paper
• Date of Acceptance

  year unknowncited by this paper

• Challenges and Optimization of Percutaneous Coronary Interventions for Coronary Bifurcation Lesions

  2026cites this paper
• Bioinspired Coronary Stents: A Technological Perspective on Exosome-Mimetic Nanoengineering and Mini-Review of Existing Platforms

  2025cites this paper
• Smart and Biodegradable Polymers in Tissue Engineering and Interventional Devices: A Brief Review

  2025cites this paper
• Biodegradable Polymeric Stent: Poly(lactic acid) Variation

  2023cites this paper
• Nanoindentation of Polymeric Stent

  2021cites this paper
• Recent Advances in Nanomaterials for Therapy and Diagnosis of Cardiovascular Disease

  2021cites this paper
• Coronary Artery Disease and The Evolution of Angioplasty Devices

  2020cites this paper
• Design and in vitro evaluation of electrospun shape memory polyurethanes for self-fitting tissue engineering grafts and drug delivery systems.

  2020cites this paper
• Evolution of Angioplasty Devices

  2020cites this paper
• Assessing the triad of biocompatibility, medical device functionality and biological safety

  2020cites this paper
• Additive Manufacturing in Vascular Stent Fabrication

  2019cites this paper
• Focus sur les dispositifs biorésorbables dans la revascularisation de la maladie coronarienne

  2019cites this paper
• Bioreactivity of Stent Material: In Vitro Impact of New Twinning-Induced Plasticity Steel on Platelet Activation

  2019cites this paper
• Das Sicherheitsprofil bioresorbierbarer Scaffolds im Vergleich mit Drug-eluting Stents in klinischen Studien

  2018cites this paper
• Development of next generation cardiovascular therapeutics through bio-assisted nanotechnology.

  2018cites this paper
• Magnesium ion leachables induce a conversion of contractile vascular smooth muscle cells to an inflammatory phenotype.

  2018cites this paper
• Basic Concepts and Clinical Outcomes of Drug-Eluting Balloons for Treatment of Coronary Artery Disease: An Overview.

  2017cites this paper